Oncology Companion Diagnostics Market Grows with Targeted Cancer Therapies and Regulatory Approvals | Agilent Technologies, Inc., Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc.

Oncology companion diagnostics market is estimated to reach at a CAGR of 12% during the forecast period (2023-2030).

Oncology Companion Diagnostics Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With the rise of targeted cancer the

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/oncology-companion-diagnostics-market?ophp

These are tests used alongside cancer therapies to determine their efficacy and safety for specific patients based on genetic markers. The market is driven by the increasing approval of targeted therapies, personalized treatment approaches, and a surge in oncology R&D investments.

Oncology Companion Diagnostics Market Competitors Overview:

Agilent Technologies, Inc., Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., ARUP Laboratories, Abbott, Myriad Genetics, Inc., bioMérieux SA, Invivoscribe, Inc., Pillar Biosciences, Inc.

Important Industry Updates of 2025:

✅ January 17, 2025 - The FDA approved FoundationOne CDx as the first companion diagnostic for tovorafenib (Ojemda), intended for pediatric low-grade glioma patients with BRAF mutations or rearrangements

✅ Myriad Genetics debuted in early 2025 a next-gen NGS-based CDx platform targeting rare melanoma mutations, improving early detection and patient stratification

Methodology and Scope

The Oncology Companion Diagnostics Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/oncology-companion-diagnostics-market?ophp

Oncology Companion Diagnostics Market Segments Overview:

∎ By Product (Instrument, Consumables, Software)
∎ By Technology (Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), Other)
∎ By End User (Hospital, Diagnostic Laboratory, Other)

The PCR-based companion diagnostics segment dominates the market because of its cost-effectiveness, wide availability, and ability to detect mutations for targeted cancer therapies.

Regional Overview for Oncology Companion Diagnostics Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

North America is the largest market, driven by co-developed therapies and FDA approvals. Asia Pacific is the fastest growing with growing personalized medicine uptake.

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=oncology-companion-diagnostics-market?ophp

The Report Covers:

➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.

People Also Ask:

➤ What are the current global trends in sales, production, imports, and exports within the Oncology Companion Diagnostics market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the Oncology Companion Diagnostics market?

Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription?ophp

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.